Key result
Moxonidine dose-dependently lowers BP, reverses LVH, and modulates ANP release in hypertensive rats.
Why the study?
Does moxonidine reduce blood pressure and reverse left ventricular hypertrophy in spontaneously hypertensive rats?
Does moxonidine reduce blood pressure and reverse left ventricular hypertrophy in spontaneously hypertensive rats?
Moxonidine exerts its antihypertensive and cardioprotective effects in part through cardiac imidazoline receptors and the release of natriuretic peptides.
No takes yet. Share an insight, caveat, or question.
Preclinical rat data do not alter practice; leaves open translation of moxonidine effects to human hypertension.
Mukaddam‐Daher et al. (2004) studied Hypertension and left ventricular hypertrophy. Moxonidine vs. 0 microg kg(-1) h(-1) (control) was evaluated on Blood pressure, diuresis, natriuresis, plasma ANP, cGMP, LVH reversal, and ventricular IL-1beta. Moxonidine dose-dependently decreased blood pressure, reversed left ventricular hypertrophy, and modulated atrial natriuretic peptide synthesis and release in spontaneously hypertensive rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: